Embecta (EMBC) Shares Outstanding (Weighted Average) (2021 - 2026)
Embecta's (EMBC) quarterly Shares Outstanding (Weighted Average) came in at $59.3 million in Q1 2026, up 2.03% year-on-year from $58.1 million in Q1 2025, and up 0.86% quarter-over-quarter from $58.8 million in Q4 2025.
Embecta (EMBC) Shares Outstanding (Weighted Average) (2021 - 2026) Analysis & Trends
Embecta has disclosed Shares Outstanding (Weighted Average) across 6 years of filings, most recently posting $59.3 million for Q1 2026.
- Shares Outstanding (Weighted Average) for Q1 2026 came in at $59.3 million, up 2.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $59.3 million (up 2.03% YoY), and the FY2025 annual result was $58.3 million, up 1.09% from the prior year.
- Shares Outstanding (Weighted Average) came in at $59.3 million for Q1 2026 at Embecta, up from $58.8 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $59.3 million in Q1 2026 to a low of $57.0 million in Q3 2022.
- The 5-year median for Shares Outstanding (Weighted Average) is $57.7 million (2024), against an average of $57.8 million.
- Across the five-year window, Shares Outstanding (Weighted Average) declined 1.0% in 2023 and grew 2.03% in 2026, its largest moves.
- Embecta's Shares Outstanding (Weighted Average) stood at $57.1 million in 2022, then climbed by 0.65% to $57.5 million in 2023, then gained by 0.81% to $58.0 million in 2024, then increased by 1.46% to $58.8 million in 2025, then increased by 0.86% to $59.3 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $59.3 million (Q1 2026), $58.8 million (Q4 2025), and $58.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 354.90 Mn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | 283.14 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | 819.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 145.34 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 72.00 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 174.20 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | 195.40 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 71.43 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | 515.00 Mn |
| 10 | Embecta | 183.23 Mn | -10.17 Mn | 127.80 Mn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.30 Mn |
| Dec 31, 2025 | 58.80 Mn |
| Sep 30, 2025 | 58.31 Mn |
| Jun 30, 2025 | 58.24 Mn |
| Mar 31, 2025 | 58.12 Mn |
| Dec 31, 2024 | 57.95 Mn |
| Sep 30, 2024 | 57.68 Mn |
| Jun 30, 2024 | 57.64 Mn |
| Mar 31, 2024 | 57.58 Mn |
| Dec 31, 2023 | 57.49 Mn |
| Sep 30, 2023 | 57.25 Mn |
| Jun 30, 2023 | 57.22 Mn |
| Mar 31, 2023 | 57.26 Mn |
| Dec 31, 2022 | 57.11 Mn |
| Sep 30, 2022 | 57.02 Mn |
| Jun 30, 2022 | 57.80 Mn |
| Mar 31, 2022 | 57.80 Mn |
| Dec 31, 2021 | 57.01 Mn |
| Sep 30, 2021 | 57.01 Mn |
| Jun 30, 2021 | 57.80 Mn |